Your shopping cart is currently empty

LY310762 is a 5-HT1D receptor antagonist with Ki of 249 nM.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $29 | In Stock | In Stock | |
| 10 mg | $43 | In Stock | In Stock | |
| 25 mg | $88 | In Stock | In Stock | |
| 50 mg | $142 | In Stock | In Stock | |
| 100 mg | $229 | In Stock | In Stock | |
| 200 mg | $347 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | In Stock | In Stock |
| Description | LY310762 is a 5-HT1D receptor antagonist with Ki of 249 nM. |
| Targets&IC50 | 5-HT1D:249 nM(Ki) |
| In vitro | Following treatment with LY310762, the levels of 5-HT in animals treated with fluoxetine increased from 312±43% to a peak of 683%. In the control group, the 5-HT levels remained constant at 250%. Compared to animals that received a control vehicle injection, systemic administration of 10 mg/kg i.p. LY310762 significantly enhanced the response of 5-HT to 20 mg/kg i.p. fluoxetine. When administered alone, LY310762 notably raised the baseline levels of 5-HT above the vehicle control, achieving a maximum value of 258% compared to the pre-injection control group. |
| In vivo | LY310762 enhances potassium-induced [3H] 5-HT efflux from guinea pig cortical slices, with an EC50 of 30 nM. The maximal enhancement of potassium-induced [3H]5-HT efflux by LY310762 is approximately 40%. LY310762 exhibits a higher affinity for the guinea pig 5-HT1D receptor than for the 5-HT1B receptor. |
| Synonyms | LY310762 HCl |
| Molecular Weight | 430.94 |
| Formula | C24H27FN2O2·HCl |
| Cas No. | 192927-92-7 |
| Smiles | Cl.CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 43.1 mg/mL (100.01 mM), Sonication is recommended. H2O: 4.31 mg/mL (10 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.32 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.